Roche/Ipsen's Suspended Taspoglutide Could Become Another Diabetes Casualty
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche confirms suspension of dosing in Phase III taspoglutide program after reporting safety problems in June. But Roche's pain could be a gain for the competing GLP-1 Bydureon from Lilly/Amylin/Alkermes.
You may also be interested in...
Roche Drops Aleglitazar In Another Cardiology/Metabolics Setback
Development of dual PPAR agonist aleglitazar terminated due to fractures, renal impairment and heart failure reported in the AleCardio study, leaving another hole in Roche’s cardiovascular/metabolic pipeline.
Roche Drops Aleglitazar In Another Cardiology/Metabolics Setback
Development of dual PPAR agonist aleglitazar terminated due to fractures, renal impairment and heart failure reported in the AleCardio study, leaving another hole in Roche’s cardiovascular/metabolic pipeline.
Diabetes Leaders Lilly, Sanofi Give A Glimpse Of GLP-1 Strategy
Sanofi and Lilly, latecomers to the rising class of GLP-1 diabetes drugs, may not have much to differentiate their drugs from other offerings. But at investor forums at the American Diabetes Association meeting, they highlighted some possibilities, including hypertension data and combination therapies.